Seeking Alpha

Athersys (ATHX) +8.9% premarket after announcing its met with the FDA to discuss results of its...

Athersys (ATHX) +8.9% premarket after announcing its met with the FDA to discuss results of its recent clinical trial involving the administration of its MultiStem treatment for patients with leukemia or other conditions that place them at risk of graft vs. host disease.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs